Experimental, Clinical and Morphological Analysis of H-Ras Oncoproteins for Locally Advanced Breast Cancer

Authors

  • A. M. Zhumakayeva “International Scientific and Production Holding”, Karaganda City, Kazakhstan
  • K. D. Rakhimov “International Scientific and Production Holding”, Karaganda City, Kazakhstan; Department of Clinical Pharmacology, Kazakh National Medical University, Almaty, Kazakhstan
  • I. M. Omarova Department of Oncology and Radiology of the Karaganda Medical University, Karaganda City, Kazakhstan
  • L. I. Arystan “International Scientific and Production Holding”, Karaganda City, Kazakhstan; Department of Clinical Pharmacology of Karaganda Medical University, Karaganda City, Kazakhstan
  • S. M. Adekenov “International Scientific and Production Holding”, Karaganda City, Kazakhstan

DOI:

https://doi.org/10.3889/oamjms.2019.708

Keywords:

Breast cancer, H-Ras, Immunohistochemistry, Prognostic, Biomarker

Abstract

BACKGROUND: Activated forms of Ras are enhanced in both breast cancer as well as the cell lines with EGFR and HER2 expression. Therefore, H-Ras could be activated in breast tumours in the absence of direct mutational activation of Ras itself and could contribute to 20-50% of the cases. Expression inhibition, signal transduction interruption from H-Ras to the nucleus could become a promising therapeutic target.

AIM: The aim of this study was to investigate the clinical and morphological criteria of locally advanced breast cancer and the expression of H-Ras oncoprotein in patients who have been subjected to different regimens of farnesyltransferase inhibitor.

METHODS: H-Ras status was assessed by immunohistochemistry (IHC).

RESULTS: An association between the expressions of H-Ras and Her2/neu (p = 0.001) as well as the tumour proliferation index Ki-67 (p = 0.001) in patients with breast cancer was established. Analysis of the relationship between H-Ras expression showed a relatively strong association with progression-free survival both before the treatment (V = 0.47; p = 0.001) and after the treatment (V = 0.45; p = 0.001). These results may indicate the clinical applicability of H-Ras as a prognostic factor or serve as a therapeutic target for breast cancer treatment.

CONCLUSION: These results could indicate the potential clinical application of H-Ras as a prognostic factor or a therapeutic target for breast cancer treatment.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

Published

2019-10-10

How to Cite

1.
Zhumakayeva AM, Rakhimov KD, Omarova IM, Arystan LI, Adekenov SM. Experimental, Clinical and Morphological Analysis of H-Ras Oncoproteins for Locally Advanced Breast Cancer. Open Access Maced J Med Sci [Internet]. 2019 Oct. 10 [cited 2024 Mar. 28];7(19):3153-7. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2019.708

Issue

Section

A - Basic Science

Most read articles by the same author(s)